Literature DB >> 25410856

Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.

Peter Abbink1, Lori F Maxfield1, David Ng'ang'a1, Erica N Borducchi1, M Justin Iampietro1, Christine A Bricault1, Jeffrey E Teigler1, Stephen Blackmore1, Lily Parenteau1, Kshitij Wagh2, Scott A Handley3, Guoyan Zhao3, Herbert W Virgin3, Bette Korber2, Dan H Barouch4.   

Abstract

UNLABELLED: Adenovirus vectors are widely used as vaccine candidates for a variety of pathogens, including HIV-1. To date, human and chimpanzee adenoviruses have been explored in detail as vaccine vectors. The phylogeny of human and chimpanzee adenoviruses is overlapping, and preexisting humoral and cellular immunity to both are exhibited in human populations worldwide. More distantly related adenoviruses may therefore offer advantages as vaccine vectors. Here we describe the primary isolation and vectorization of three novel adenoviruses from rhesus monkeys. The seroprevalence of these novel rhesus monkey adenovirus vectors was extremely low in sub-Saharan Africa human populations, and these vectors proved to have immunogenicity comparable to that of human and chimpanzee adenovirus vaccine vectors in mice. These rhesus monkey adenoviruses phylogenetically clustered with the poorly described adenovirus species G and robustly stimulated innate immune responses. These novel adenoviruses represent a new class of candidate vaccine vectors. IMPORTANCE: Although there have been substantial efforts in the development of vaccine vectors from human and chimpanzee adenoviruses, far less is known about rhesus monkey adenoviruses. In this report, we describe the isolation and vectorization of three novel rhesus monkey adenoviruses. These vectors exhibit virologic and immunologic characteristics that make them attractive as potential candidate vaccine vectors for both HIV-1 and other pathogens.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410856      PMCID: PMC4300752          DOI: 10.1128/JVI.02950-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.

Authors:  Hualin Li; Elizabeth G Rhee; Katherine Masek-Hammerman; Jeffrey E Teigler; Peter Abbink; Dan H Barouch
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

3.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

4.  A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences.

Authors:  A C Siepel; A L Halpern; C Macken; B T Korber
Journal:  AIDS Res Hum Retroviruses       Date:  1995-11       Impact factor: 2.205

5.  Replication-defective bovine adenovirus type 3 as an expression vector.

Authors:  P S Reddy; N Idamakanti; Y Chen; T Whale; L A Babiuk; M Mehtali; S K Tikoo
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

6.  Development of a targeted gene vector platform based on simian adenovirus serotype 24.

Authors:  Natalya Belousova; Galina Mikheeva; Chiyi Xiong; Suren Soghomonian; Daniel Young; Lucia Le Roux; Katherine Naff; Luc Bidaut; Wei Wei; Chun Li; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

7.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

8.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

Review 9.  Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

Authors:  Stefania Capone; Anna Morena D'Alise; Virginia Ammendola; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  Expert Rev Vaccines       Date:  2013-04       Impact factor: 5.217

10.  Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Authors:  Stefano Colloca; Eleanor Barnes; Antonella Folgori; Virginia Ammendola; Stefania Capone; Agostino Cirillo; Loredana Siani; Mariarosaria Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Maria Ambrosio; Angela Sparacino; Marta Bartiromo; Annalisa Meola; Kira Smith; Ayako Kurioka; Geraldine A O'Hara; Katie J Ewer; Nicholas Anagnostou; Carly Bliss; Adrian V S Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

View more
  25 in total

Review 1.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

2.  Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.

Authors:  Pablo Penaloza MacMaster; Jennifer L Shields; Quazim A Alayo; Crystal Cabral; Jessica Jimenez; Jade Mondesir; Abishek Chandrashekar; Joseph M Cabral; Matthew Lim; M Justin Iampietro; Nicholas M Provine; Christine A Bricault; Michael Seaman; Klaus Orlinger; Andreas Aspoeck; Gerhard Fuhrmann; Anders E Lilja; Thomas Monath; Bastien Mangeat; Daniel D Pinschewer; Dan H Barouch
Journal:  Vaccine       Date:  2016-11-26       Impact factor: 3.641

3.  The Coxsackievirus and Adenovirus Receptor, a Required Host Factor for Recovirus Infection, Is a Putative Enteric Calicivirus Receptor.

Authors:  Tibor Farkas; Kui Yang; Jacques Le Pendu; Joel D Baines; Rhonda D Cardin
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

4.  Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.

Authors:  Kun Xu; Yufeng Song; Lianpan Dai; Yongli Zhang; Xuancheng Lu; Yijia Xie; Hangjie Zhang; Tao Cheng; Qihui Wang; Qingrui Huang; Yuhai Bi; William J Liu; Wenjun Liu; Xiangdong Li; Chuan Qin; Yi Shi; Jinghua Yan; Dongming Zhou; George F Gao
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 5.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

6.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

7.  Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.

Authors:  Sara R Privatt; Brianna L Bullard; Eric A Weaver; Charles Wood; John T West
Journal:  Vaccine       Date:  2019-08-01       Impact factor: 3.641

8.  Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Authors:  Peter Abbink; Rafael A Larocca; Rafael A De La Barrera; Christine A Bricault; Edward T Moseley; Michael Boyd; Marinela Kirilova; Zhenfeng Li; David Ng'ang'a; Ovini Nanayakkara; Ramya Nityanandam; Noe B Mercado; Erica N Borducchi; Arshi Agarwal; Amanda L Brinkman; Crystal Cabral; Abishek Chandrashekar; Patricia B Giglio; David Jetton; Jessica Jimenez; Benjamin C Lee; Shanell Mojta; Katherine Molloy; Mayuri Shetty; George H Neubauer; Kathryn E Stephenson; Jean Pierre S Peron; Paolo M de A Zanotto; Johnathan Misamore; Brad Finneyfrock; Mark G Lewis; Galit Alter; Kayvon Modjarrad; Richard G Jarman; Kenneth H Eckels; Nelson L Michael; Stephen J Thomas; Dan H Barouch
Journal:  Science       Date:  2016-08-04       Impact factor: 47.728

9.  Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization.

Authors:  Lori F Maxfield; Peter Abbink; Kathryn E Stephenson; Erica N Borducchi; David Ng'ang'a; Marinela M Kirilova; Noelix Paulino; Michael Boyd; Paul Shabram; Qian Ruan; Mayank Patel; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

10.  Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2.

Authors:  Lisa H Tostanoski; Lisa E Gralinski; David R Martinez; Alexandra Schaefer; Shant H Mahrokhian; Zhenfeng Li; Felix Nampanya; Huahua Wan; Jingyou Yu; Aiquan Chang; Jinyan Liu; Katherine McMahan; Kenneth H Dinnon; Sarah R Leist; Ralph S Baric; Dan H Barouch
Journal:  bioRxiv       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.